Oncolytics Historical Income Statement

ONCY Stock

USD 0.93 0.02 2.11%

Historical analysis of Oncolytics Biotech income statement accounts such as Total Revenue of 0.0 can show how well Oncolytics Biotech performed in making a profits. Evaluating Oncolytics Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Oncolytics Biotech's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Oncolytics Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Oncolytics Biotech is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

About Oncolytics Income Statement Analysis

Oncolytics Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Oncolytics Biotech shareholders. The income statement also shows Oncolytics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Oncolytics Biotech Income Statement Chart

At this time, Oncolytics Biotech's Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 16.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 77 K in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Oncolytics Biotech. It is also known as Oncolytics Biotech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Oncolytics Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 16.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 77 K in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	98.6K	528K	1.2M	1.2M
Net Interest Income	98.6K	528K	1.2M	1.2M

Interest Income Net Interest Income

Oncolytics Biotech income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Net Income From Continuing Ops	Cost Of Revenue	Income Before Tax	Total Other Income Expense Net	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.12	0.02	-0.01	0.04	0.04	-0.1	0.37	-0.01	-0.6	0.97	-0.4	-0.11	-0.36	-0.76	-0.14	-0.11	-0.11	0.45	-0.13
Selling General Administrative	0.12		0.18	0.27	-0.43	-0.43	-0.13	-0.36	0.26	-0.29	0.05	-0.93	-0.53	-0.31	0.31	0.18	0.67	0.67	0.83	0.69
Gross Profit	0.02	0.18		-0.27	0.24	0.23	-0.36	0.22	-0.27	0.23	0.01	-0.24	-0.61	0.28	0.04	0.14	0.05	0.05	0.08	0.06
Other Operating Expenses	-0.01	0.27	-0.27		-0.94	-0.94	0.89	-0.87	1.0	-0.73	-0.06	-0.2	0.23	-0.86	0.2	-0.1	0.26	0.26	0.36	0.29
Operating Income	0.04	-0.43	0.24	-0.94		1.0	-0.83	0.94	-0.93	0.75	0.07	0.31	-0.18	0.9	-0.33	0.08	-0.49	-0.49	-0.43	-0.5
Ebit	0.04	-0.43	0.23	-0.94	1.0		-0.83	0.94	-0.93	0.75	0.07	0.31	-0.17	0.9	-0.33	0.08	-0.49	-0.49	-0.43	-0.49
Research Development	-0.1	-0.13	-0.36	0.89	-0.83	-0.83		-0.81	0.89	-0.65	-0.1	0.19	0.51	-0.8	0.14	-0.19	0.09	0.09	-0.02	0.1
Ebitda	0.37	-0.36	0.22	-0.87	0.94	0.94	-0.81		-0.87	0.5	0.39	0.16	-0.19	0.72	-0.56	0.03	-0.49	-0.49	-0.25	-0.5
Total Operating Expenses	-0.01	0.26	-0.27	1.0	-0.93	-0.93	0.89	-0.87		-0.72	-0.05	-0.19	0.23	-0.86	0.19	-0.1	0.25	0.25	0.35	0.29
Net Income	-0.6	-0.29	0.23	-0.73	0.75	0.75	-0.65	0.5	-0.72		-0.59	0.39	-0.15	0.96	0.29	0.14	-0.23	-0.23	-0.51	-0.22
Income Tax Expense	0.97	0.05	0.01	-0.06	0.07	0.07	-0.1	0.39	-0.05	-0.59		-0.34	-0.08	-0.33	-0.77	-0.06	-0.06	-0.06	0.32	-0.09
Net Income From Continuing Ops	-0.4	-0.93	-0.24	-0.2	0.31	0.31	0.19	0.16	-0.19	0.39	-0.34		0.59	0.32	-0.01	-0.19	-0.54	-0.54	-0.84	-0.57
Cost Of Revenue	-0.11	-0.53	-0.61	0.23	-0.18	-0.17	0.51	-0.19	0.23	-0.15	-0.08	0.59		-0.25	0.01	-0.26	-0.17	-0.17	-0.31	-0.2
Income Before Tax	-0.36	-0.31	0.28	-0.86	0.9	0.9	-0.8	0.72	-0.86	0.96	-0.33	0.32	-0.25		0.06	0.16	-0.3	-0.3	-0.48	-0.3
Total Other Income Expense Net	-0.76	0.31	0.04	0.2	-0.33	-0.33	0.14	-0.56	0.19	0.29	-0.77	-0.01	0.01	0.06		0.06	0.58	0.58	0.03	0.57
Tax Provision	-0.14	0.18	0.14	-0.1	0.08	0.08	-0.19	0.03	-0.1	0.14	-0.06	-0.19	-0.26	0.16	0.06		0.09	0.09	-0.11	0.09
Net Interest Income	-0.11	0.67	0.05	0.26	-0.49	-0.49	0.09	-0.49	0.25	-0.23	-0.06	-0.54	-0.17	-0.3	0.58	0.09		1.0	0.42	0.95
Interest Income	-0.11	0.67	0.05	0.26	-0.49	-0.49	0.09	-0.49	0.25	-0.23	-0.06	-0.54	-0.17	-0.3	0.58	0.09	1.0		0.42	0.95
Reconciled Depreciation	0.45	0.83	0.08	0.36	-0.43	-0.43	-0.02	-0.25	0.35	-0.51	0.32	-0.84	-0.31	-0.48	0.03	-0.11	0.42	0.42		0.49
Selling And Marketing Expenses	-0.13	0.69	0.06	0.29	-0.5	-0.49	0.1	-0.5	0.29	-0.22	-0.09	-0.57	-0.2	-0.3	0.57	0.09	0.95	0.95	0.49

Click cells to compare fundamentals

Oncolytics Biotech Account Relationship Matchups

Oncolytics Biotech income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	13.1M	446.2K	452.1K	392K	81K	77.0K
Selling General Administrative	9.6M	12.5M	13.3M	11.5M	16.1M	16.9M
Gross Profit	(485.6K)	(446.2K)	(452.1K)	(392K)	(403K)	(423.2K)
Other Operating Expenses	20.7M	25.5M	26.2M	26.9M	33.8M	19.5M
Operating Income	(20.7M)	(25.5M)	(26.2M)	(28.6M)	(33.8M)	(32.1M)
Ebit	(20.7M)	(25.8M)	(26.1M)	(27.2M)	(33.8M)	(32.1M)
Research Development	11.1M	12.9M	12.9M	15.4M	17.7M	12.6M
Ebitda	(7.6M)	(25.4M)	(25.7M)	(26.8M)	(33.7M)	(32.0M)
Total Operating Expenses	20.7M	25.5M	26.2M	26.9M	33.8M	19.1M
Net Income	(45.6M)	(19.6M)	(26.3M)	(24.8M)	(27.8M)	(29.1M)
Income Tax Expense	12.4M	(3.0M)	49.4K	84K	97K	92.2K
Net Income From Continuing Ops	(33.1M)	(22.5M)	(26.3M)	(24.8M)	(32.4M)	(30.7M)
Cost Of Revenue	485.6K	446.2K	452.1K	392K	403K	382.9K
Income Before Tax	(33.1M)	(22.5M)	(26.3M)	(24.8M)	(27.7M)	(29.0M)
Total Other Income Expense Net	(12.4M)	3.0M	(20.1K)	2.2M	6.1M	6.4M
Net Income Applicable To Common Shares	(33.1M)	(22.5M)	(26.3M)	(24.8M)	(22.4M)	(21.2M)
Net Interest Income	179.3K	121.2K	98.6K	528K	1.2M	1.2M
Interest Income	179.3K	121.2K	98.6K	528K	1.2M	1.2M
Reconciled Depreciation	485.6K	446.2K	452.1K	392K	395K	370.4K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncolytics Historical Income Statement

About Oncolytics Income Statement Analysis

Oncolytics Biotech Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Oncolytics Biotech income statement Correlations

Oncolytics Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncolytics Biotech income statement Accounts

Also Currently Popular

Additional Tools for Oncolytics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Total Revenue
Gross Profit	Other Operating Expenses
Operating Income	Ebit
Research Development	Ebitda
Total Operating Expenses	Net Income
Income Tax Expense	Discontinued Operations
Net Income From Continuing Ops	Cost Of Revenue
Non Recurring	Effect Of Accounting Charges
Income Before Tax	Extraordinary Items
Total Other Income Expense Net	Net Income Applicable To Common Shares
Minority Interest	Other Items
Tax Provision	Preferred Stock And Other Adjustments
Non Operating Income Net Other	Net Interest Income
Interest Income	Reconciled Depreciation
Selling And Marketing Expenses

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Interest Income	+ 1.0	Net Interest Income
Income Tax Expense	+ 0.97	Depreciation And Amortization
Income Before Tax	+ 0.96	Net Income
Selling And Marketing Expenses	+ 0.95	Net Interest Income

Ebit	- 0.94	Other Operating Expenses
Operating Income	- 0.94	Other Operating Expenses
Total Operating Expenses	- 0.93	Ebit
Total Operating Expenses	- 0.93	Operating Income
Net Income From Continuing Ops	- 0.93	Selling General Administrative
Total Operating Expenses	- 0.87	Ebitda